Skip to main content

Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.

Publication ,  Journal Article
Simó, R; Roy, S; Behar-Cohen, F; Keech, A; Mitchell, P; Wong, TY
Published in: Curr Med Chem
2013

Despite improving standards of care, people with diabetes remain at risk of development and progression of diabetic retinopathy (DR) and visual impairment. Identifying novel therapeutic approaches, preferably targeting more than one pathogenic pathway in DR, and at an earlier stage of disease, is attractive. There is now consistent evidence from two major trials, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study and the Action to Control Cardiovascular Risk in Diabetes Eye (ACCORD-Eye) study, totalling 11,388 people with type 2 diabetes (5,701 treated with fenofibrate) that fenofibrate reduces the risk of development and progression of DR. Therefore, fenofibrate may be considered a preventive strategy for patients without DR or early intervention strategy for those with mild DR. A number of putative therapeutic mechanisms for fenofibrate, both dependent and independent of lipids, have been proposed. A deeper understanding of the mode of action of fenofibrate will further help to define how best to use fenofibrate clinically as an adjunct to current management of DR.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Med Chem

DOI

EISSN

1875-533X

Publication Date

2013

Volume

20

Issue

26

Start / End Page

3258 / 3266

Location

United Arab Emirates

Related Subject Headings

  • Medicinal & Biomolecular Chemistry
  • Hypolipidemic Agents
  • Humans
  • Fenofibrate
  • Disease Progression
  • Diabetic Retinopathy
  • Diabetes Mellitus, Type 2
  • Animals
  • 3404 Medicinal and biomolecular chemistry
  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Simó, R., Roy, S., Behar-Cohen, F., Keech, A., Mitchell, P., & Wong, T. Y. (2013). Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem, 20(26), 3258–3266. https://doi.org/10.2174/0929867311320260009
Simó, Rafael, Sayon Roy, Francine Behar-Cohen, Anthony Keech, Paul Mitchell, and Tien Yin Wong. “Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.Curr Med Chem 20, no. 26 (2013): 3258–66. https://doi.org/10.2174/0929867311320260009.
Simó R, Roy S, Behar-Cohen F, Keech A, Mitchell P, Wong TY. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem. 2013;20(26):3258–66.
Simó, Rafael, et al. “Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.Curr Med Chem, vol. 20, no. 26, 2013, pp. 3258–66. Pubmed, doi:10.2174/0929867311320260009.
Simó R, Roy S, Behar-Cohen F, Keech A, Mitchell P, Wong TY. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem. 2013;20(26):3258–3266.

Published In

Curr Med Chem

DOI

EISSN

1875-533X

Publication Date

2013

Volume

20

Issue

26

Start / End Page

3258 / 3266

Location

United Arab Emirates

Related Subject Headings

  • Medicinal & Biomolecular Chemistry
  • Hypolipidemic Agents
  • Humans
  • Fenofibrate
  • Disease Progression
  • Diabetic Retinopathy
  • Diabetes Mellitus, Type 2
  • Animals
  • 3404 Medicinal and biomolecular chemistry
  • 3214 Pharmacology and pharmaceutical sciences